Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
EyePoint Pharmaceuticals, Inc. stock logo
EYPT
EyePoint Pharmaceuticals
$8.86
+0.6%
$6.44
$3.91
$13.99
$609.67M1.61814,668 shs790,408 shs
Standard BioTools Inc. stock logo
LAB
Standard BioTools
$1.05
-2.8%
$1.10
$0.92
$2.41
$398.81M1.52.08 million shs498,566 shs
Transcat, Inc. stock logo
TRNS
Transcat
$77.39
+2.4%
$82.27
$67.56
$147.12
$721.12M0.7585,743 shs158,186 shs
10x Genomics, Inc. stock logo
TXG
10x Genomics
$10.58
-1.9%
$8.68
$6.78
$24.76
$1.30B1.992.54 million shs3.27 million shs
10 Stocks Set to Soar in Summer 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
EyePoint Pharmaceuticals, Inc. stock logo
EYPT
EyePoint Pharmaceuticals
+0.57%+7.39%+49.92%+35.89%-4.94%
Standard BioTools Inc. stock logo
LAB
Standard BioTools
-2.78%+6.06%-7.89%-7.89%-54.94%
Transcat, Inc. stock logo
TRNS
Transcat
+2.42%-3.53%-4.96%+6.64%-38.06%
10x Genomics, Inc. stock logo
TXG
10x Genomics
-1.86%+16.14%+9.64%+2.32%-50.44%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
EyePoint Pharmaceuticals, Inc. stock logo
EYPT
EyePoint Pharmaceuticals
2.4473 of 5 stars
3.52.00.00.04.01.70.0
Standard BioTools Inc. stock logo
LAB
Standard BioTools
2.6894 of 5 stars
3.32.00.00.02.73.30.6
Transcat, Inc. stock logo
TRNS
Transcat
2.9549 of 5 stars
3.33.00.00.01.71.71.9
10x Genomics, Inc. stock logo
TXG
10x Genomics
4.2478 of 5 stars
4.21.00.04.81.32.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
EyePoint Pharmaceuticals, Inc. stock logo
EYPT
EyePoint Pharmaceuticals
3.00
Buy$25.38186.40% Upside
Standard BioTools Inc. stock logo
LAB
Standard BioTools
2.50
Moderate Buy$2.50138.10% Upside
Transcat, Inc. stock logo
TRNS
Transcat
2.50
Moderate Buy$114.0047.31% Upside
10x Genomics, Inc. stock logo
TXG
10x Genomics
2.38
Hold$15.8149.41% Upside

Current Analyst Ratings Breakdown

Latest LAB, TXG, TRNS, and EYPT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/11/2025
10x Genomics, Inc. stock logo
TXG
10x Genomics
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (E+) ➝ Sell (E+)
5/29/2025
EyePoint Pharmaceuticals, Inc. stock logo
EYPT
EyePoint Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$22.00
5/24/2025
10x Genomics, Inc. stock logo
TXG
10x Genomics
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (E+) ➝ Sell (E+)
5/21/2025
Transcat, Inc. stock logo
TRNS
Transcat
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$106.00 ➝ $116.00
5/19/2025
10x Genomics, Inc. stock logo
TXG
10x Genomics
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$26.00 ➝ $18.00
5/16/2025
EyePoint Pharmaceuticals, Inc. stock logo
EYPT
EyePoint Pharmaceuticals
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$30.00 ➝ $26.00
5/15/2025
10x Genomics, Inc. stock logo
TXG
10x Genomics
Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$14.00 ➝ $14.00
5/13/2025
10x Genomics, Inc. stock logo
TXG
10x Genomics
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$14.00 ➝ $12.00
5/12/2025
10x Genomics, Inc. stock logo
TXG
10x Genomics
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSell ➝ Sell$7.50 ➝ $6.50
5/12/2025
10x Genomics, Inc. stock logo
TXG
10x Genomics
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$18.00 ➝ $15.00
5/10/2025
10x Genomics, Inc. stock logo
TXG
10x Genomics
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (E+) ➝ Sell (E+)
(Data available from 6/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
EyePoint Pharmaceuticals, Inc. stock logo
EYPT
EyePoint Pharmaceuticals
$56.04M10.88N/AN/A$5.66 per share1.57
Standard BioTools Inc. stock logo
LAB
Standard BioTools
$169.69M2.35N/AN/A($1.85) per share-0.57
Transcat, Inc. stock logo
TRNS
Transcat
$278.42M2.59$2.85 per share27.14$30.19 per share2.56
10x Genomics, Inc. stock logo
TXG
10x Genomics
$624.66M2.09N/AN/A$5.81 per share1.82
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
EyePoint Pharmaceuticals, Inc. stock logo
EYPT
EyePoint Pharmaceuticals
-$70.79M-$2.41N/AN/AN/A-226.57%-43.01%-31.63%8/6/2025 (Estimated)
Standard BioTools Inc. stock logo
LAB
Standard BioTools
-$74.66M-$0.35N/AN/AN/A-79.92%-27.05%-15.52%7/30/2025 (Estimated)
Transcat, Inc. stock logo
TRNS
Transcat
$13.65M$1.5641.8329.43N/A6.22%7.23%5.67%8/4/2025 (Estimated)
10x Genomics, Inc. stock logo
TXG
10x Genomics
-$182.63M-$1.30N/AN/AN/A-29.90%-25.40%-19.69%8/6/2025 (Estimated)

Latest LAB, TXG, TRNS, and EYPT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/19/2025Q4 2025
Transcat, Inc. stock logo
TRNS
Transcat
$0.66$0.64-$0.02$0.48$76.40 million$77.13 million
5/8/2025Q1 2025
10x Genomics, Inc. stock logo
TXG
10x Genomics
-$0.45-$0.36+$0.09-$0.28$131.91 million$154.88 million
5/7/2025Q1 2025
EyePoint Pharmaceuticals, Inc. stock logo
EYPT
EyePoint Pharmaceuticals
-$0.65-$0.65N/A-$0.65$8.84 million$24.50 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
EyePoint Pharmaceuticals, Inc. stock logo
EYPT
EyePoint Pharmaceuticals
N/AN/AN/AN/AN/A
Standard BioTools Inc. stock logo
LAB
Standard BioTools
N/AN/AN/AN/AN/A
Transcat, Inc. stock logo
TRNS
Transcat
N/AN/AN/AN/AN/A
10x Genomics, Inc. stock logo
TXG
10x Genomics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
EyePoint Pharmaceuticals, Inc. stock logo
EYPT
EyePoint Pharmaceuticals
N/A
5.50
5.45
Standard BioTools Inc. stock logo
LAB
Standard BioTools
N/A
3.76
3.41
Transcat, Inc. stock logo
TRNS
Transcat
0.14
2.42
1.98
10x Genomics, Inc. stock logo
TXG
10x Genomics
N/A
4.97
4.26

Institutional Ownership

CompanyInstitutional Ownership
EyePoint Pharmaceuticals, Inc. stock logo
EYPT
EyePoint Pharmaceuticals
99.41%
Standard BioTools Inc. stock logo
LAB
Standard BioTools
53.74%
Transcat, Inc. stock logo
TRNS
Transcat
98.34%
10x Genomics, Inc. stock logo
TXG
10x Genomics
84.68%

Insider Ownership

CompanyInsider Ownership
EyePoint Pharmaceuticals, Inc. stock logo
EYPT
EyePoint Pharmaceuticals
4.46%
Standard BioTools Inc. stock logo
LAB
Standard BioTools
23.16%
Transcat, Inc. stock logo
TRNS
Transcat
2.30%
10x Genomics, Inc. stock logo
TXG
10x Genomics
9.39%
CompanyEmployeesShares OutstandingFree FloatOptionable
EyePoint Pharmaceuticals, Inc. stock logo
EYPT
EyePoint Pharmaceuticals
12068.81 million65.02 millionOptionable
Standard BioTools Inc. stock logo
LAB
Standard BioTools
620379.82 million174.59 millionOptionable
Transcat, Inc. stock logo
TRNS
Transcat
9209.32 million9.10 millionOptionable
10x Genomics, Inc. stock logo
TXG
10x Genomics
1,240123.13 million108.91 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
EyePoint Pharmaceuticals stock logo

EyePoint Pharmaceuticals NASDAQ:EYPT

$8.86 +0.05 (+0.57%)
Closing price 06/12/2025 04:00 PM Eastern
Extended Trading
$9.07 +0.21 (+2.37%)
As of 07:53 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

EyePoint Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 2 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.

Standard BioTools stock logo

Standard BioTools NASDAQ:LAB

$1.05 -0.03 (-2.78%)
Closing price 06/12/2025 04:00 PM Eastern
Extended Trading
$1.05 0.00 (0.00%)
As of 07:07 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Standard BioTools Inc., together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument. It also provides genomics, such as X9 Real-Time PCR System, a real-time PCR analytical instrument including pre-processing steps for microfluidics-based workflows using (integrated fluidic circuit) IFCs; and IFC Controllers, a controller which is designed to work with IFC formats. In addition, the company offers analytical instruments comprising Biomark HD system, a real-time PCR analytical instrument for microfluidics-based workflows using prepared IFCs. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.

Transcat stock logo

Transcat NASDAQ:TRNS

$77.39 +1.83 (+2.42%)
As of 06/12/2025 04:00 PM Eastern

Transcat, Inc. provides calibration and laboratory instrument services in the United States, Canada, and internationally. It operates through two segments: Service and Distribution. The Service segment offers calibration, repair, inspection, analytical qualification, preventative maintenance, consulting, and other related services. This segment also provides CalTrak, a proprietary document and asset management system that is used to manage the workflow of its calibration service centers and customers' assets; and Compliance, Control and Cost, an online customer portal that provides its customers with web-based asset management capability, as well as a safe and secure off-site archive of calibration and other service records. The Distribution segment sells and rents test, measurement, and control instruments for customers' test and measurement instrumentation needs, as well as value added services, such as calibration/certification of equipment purchase, equipment rental, used equipment for sale, and equipment kitting. This segment markets and sells its products through website, digital and print advertising, proactive outbound sales, and an inbound call center. The company provides services and products to highly regulated industries, principally life science, which includes companies in the pharmaceutical, biotechnology, medical device, and other FDA-regulated industries; and additional industries, including aerospace and defense industrial manufacturing, energy and utilities, and other industries that require accuracy in processes and confirmation of the capabilities of their equipment. Transcat, Inc. was incorporated in 1964 and is headquartered in Rochester, New York.

10x Genomics stock logo

10x Genomics NASDAQ:TXG

$10.58 -0.20 (-1.86%)
Closing price 06/12/2025 04:00 PM Eastern
Extended Trading
$10.31 -0.27 (-2.55%)
As of 07:51 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell. The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.